Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2025)

Zevra Therapeutics' Gross Margin history spans 6 years, with the latest figure at 95.55% for Q4 2025.

  • For Q4 2025, Gross Margin rose 690.0% year-over-year to 95.55%; the TTM value through Dec 2025 reached 84.53%, up 1599.0%, while the annual FY2025 figure was 84.52%, 1595.0% up from the prior year.
  • Gross Margin reached 95.55% in Q4 2025 per ZVRA's latest filing, roughly flat from 95.26% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q3 2021 to a low of 19.69% in Q2 2024.
  • Average Gross Margin over 5 years is 82.21%, with a median of 94.85% recorded in 2024.
  • Peak YoY movement for Gross Margin: tumbled -7398bps in 2022, then soared 6901bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 97.71% in 2021, then rose by 1bps to 98.48% in 2022, then decreased by -8bps to 90.5% in 2023, then dropped by -2bps to 88.65% in 2024, then grew by 8bps to 95.55% in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Gross Margin are 95.55% (Q4 2025), 95.26% (Q3 2025), and 52.2% (Q2 2025).